Immunotherapy with tumor vaccines for the treatment of malignant gliomas.

Published

Journal Article (Review)

With an average life expectancy of 14 months, Glioblastoma multiforme (GBM), is the most aggressive primary brain tumor. Our growing understanding of the immune system and its role in oncogenesis has helped develop cancer vaccines as a promising treatment modality against this disease. What follows is a comprehensive discussion on the history of immunotherapy and the various vaccine based therapies being developed and utilized for the treatment of malignant gliomas.

Full Text

Duke Authors

Cited Authors

  • Ajay, D; Sanchez-Perez, L; Choi, BD; De Leon, G; Sampson, JH

Published Date

  • December 2012

Published In

Volume / Issue

  • 9 / 4

Start / End Page

  • 237 - 255

PubMed ID

  • 22339070

Pubmed Central ID

  • 22339070

Electronic International Standard Serial Number (EISSN)

  • 1875-6220

Language

  • eng

Conference Location

  • United Arab Emirates